Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery

Comparison of Three Different Doses Sugammadex Based on Ideal Body Weight for Reversal of Moderate Rocuronium-induced Neuromuscular Blockade in Laparoscopic Bariatric Surgery.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02713113

Enrollment

180

Registered

2016-03-18

Start date

2015-03-31

Completion date

2016-03-31

Last updated

2016-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Patients

Brief summary

the investigators aimed to compare the efficacy and safety of sugammadex at doses of 1.5, 2, and 4 mg/ kg for the reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery.

Detailed description

Patients were randomly assigned using a randomization-computer program into three groups according to the dose of sugammadex administrated (according to the IBW after T2 of TOF): Group I: patients were given 1.5 mg / kg. Group II: patients were given 2 mg / kg. Group III: patients were given 4 mg / kg.

Interventions

DRUGsugammadex reversal of neuromuscular blockade

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* morbidly obese patients of both sex (BMI \> 40 kg.m-2) * scheduled for elective laparoscopic bariatric surgery (gastric bypass or sleeve surgery) under general anesthesia using rocuronium for tracheal intubation and maintenance of NMB * aged between 18 and 60 years and classified as ASA II - III

Exclusion criteria

* liver and renal dysfunction, * disabling neuropsychiatric disorders, * history of stroke, brain trauma in the last 12 months * hypersensitivity to anesthetics, history of myocardial infarction, congestive heart failure * difficult tracheal intubation, and known or suspected disorder affecting NMB.

Design outcomes

Primary

Measure	Time frame
sugammadex time following a dose of 1.5 mg / kg of sugammadex according to IBW in comparison to 2, and 4 mg / kg,	2 hrs

Secondary

Measure	Time frame
extubation time	2 hrs

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026